EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Hyaluronan accumulation is associated with reduced hyaluronidase expression in renal cell carcinoma, with CD44 , HAS1 , and HYAL2 emerging as prognostic markers

Otto Jokelainen iD, Teemu Rintala iD, Satu Remes, Sanna Pasonen-Seppänen, Timo K Nykopp, Reijo Sironen

The Journal of Pathology: Clinical Research · 2025

DOI: 10.1002/2056-4538.70035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pathology: Clinical Research, 2025. Verfasst von Otto Jokelainen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Eastern Finland, Kuopio, Finland. Hauptthemen laut MEDLINE: Hyaluronan Receptors, Carcinoma, Renal Cell, Hyaluronoglucosaminidase, Kidney Neoplasms. Die Arbeit nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Kuopio University Hospital Research Foundation, Munuaissäätiö, The Finnish Medical Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hyaluronan (HA), a large extracellular matrix glycosaminoglycan, is associated with malignant features in several human cancers. The accumulation of HA in renal cell carcinomas (RCC) correlates with unfavorable outcomes, higher tumor grade, and more advanced disease stages. However, the mechanisms responsible for HA buildup in these neoplasms remain unclear, and studies on the expression of hyaluronan‐metabolizing and ‐degrading enzymes are either lacking or conflicting. This study aims to address this knowledge gap. Formalin‐fixed paraffin‐embedded (FFPE) RCC samples of various histological subtypes from 315 patients were immunohistochemically stained for CD44 (the main receptor of HA), hyaluronan‐synthesizing enzymes HAS1–3, and degrading enzymes HYAL1–2. Protein expression levels were correlated with clinicopathological variables and their prognostic significance was evaluated. Additionally, the mRNA expression levels of these proteins were examined using RNA extracted from the same samples and publicly available data from the cancer genome atlas (TCGA). CD44 protein expression was associated with increased tumoral HA content, poor prognosis, higher tumor grade, advanced stage, and sarcomatoid/rhabdoid changes. HYAL1 and HYAL2 protein levels were reduced in HA‐positive tumors, and low HYAL2 expression predicted worse prognosis. Elevated HAS2 protein expression was associated with poor differentiation, while low HAS1 protein levels were associated with reduced survival. mRNA levels of CD44 and HYAL2 correlated with their respective protein expression levels, and CD44 mRNA expression was also associated with HA content. In RCC, HA accumulation appears to be primarily driven by decreased degradation. HAS1 and HYAL2 were identified as novel prognostic biomarkers. These findings provide new insights into HA metabolism in RCC and open potential avenues for better understanding and management of these tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hyaluronan ReceptorsCarcinoma, Renal CellHyaluronoglucosaminidaseKidney NeoplasmsHyaluronic AcidBiomarkers, TumorHyaluronan SynthasesCell Adhesion MoleculesHumansFemaleMaleMiddle AgedAgedPrognosisAdultAged, 80 and overGPI-Linked Proteins

Stichwörter der Autor:innen

hyaluronanhyaluronan synthasehyaluronidaseprognosisrenal cell carcinoma

Substanzen

Hyaluronan ReceptorsHyaluronoglucosaminidaseHyaluronic AcidCD44 protein, humanHyal2 protein, humanBiomarkers, TumorHAS1 protein, humanHyaluronan SynthasesCell Adhesion MoleculesGPI-Linked Proteins

Autor:innen und Institutionen

  • Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Eastern Finland, Kuopio, Finland.
  • Department of Clinical Pathology, Kuopio University Hospital, Kuopio, Finland.
  • Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.
  • Department of Surgery, Kuopio University Hospital, Kuopio, Finland.
  • Institute of Clinical Medicine, Surgery, University of Eastern Finland, Kuopio, Finland.

ORCID-Profile: Otto Jokelainen, Teemu Rintala

Förderung

  • Kuopio University Hospital Research Foundation
  • Munuaissäätiö
  • The Finnish Medical Foundation
  • Cancer Foundation Finland
  • Ida Monti Foundation
  • Cancer Society of North Savo
  • Paavo Koistinen Foundation
  • Syöpäsäätiö

Zitieren

APA

Jokelainen, O., Rintala, T., Remes, S., Pasonen-Seppänen, S., Nykopp, T. K., & Sironen, R. (2025). Hyaluronan accumulation is associated with reduced hyaluronidase expression in renal cell carcinoma, with CD44 , HAS1 , and HYAL2 emerging as prognostic markers. The Journal of Pathology: Clinical Research. https://doi.org/10.1002/2056-4538.70035

Vancouver

Jokelainen O, Rintala T, Remes S, Pasonen-Seppänen S, Nykopp TK, Sironen R. Hyaluronan accumulation is associated with reduced hyaluronidase expression in renal cell carcinoma, with CD44 , HAS1 , and HYAL2 emerging as prognostic markers. The Journal of Pathology: Clinical Research. 2025. doi:10.1002/2056-4538.70035

BibTeX
@article{Jokelainen2025,
  author = {Jokelainen, Otto and Rintala, Teemu and Remes, Satu and Pasonen-Seppänen, Sanna and Nykopp, Timo K and Sironen, Reijo},
  title = {Hyaluronan accumulation is associated with reduced hyaluronidase expression in renal cell carcinoma, with CD44 , HAS1 , and HYAL2 emerging as prognostic markers},
  journal = {The Journal of Pathology: Clinical Research},
  year = {2025},
  doi = {10.1002/2056-4538.70035}
}
Kostenlos starten →